Middle East & Africa Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)

Description

List of Tables

The Middle East & Africa vaccine adjuvants market was valued at US$ 78.94 million in 2022 and is expected to reach US$ 187.15 million by 2030; it is estimated to register a CAGR of 11.4% from 2022 to 2030 .

Technological Advancements Bolster Middle East & Africa Vaccine Adjuvants Market

Currently, aluminum salt or gel-based adjuvants are used predominantly in licensed vaccines. Monophosphoryl lipid A (MPL) adjuvant and hydrophobic copolymers are examples of these components. Hydrophobic microspheres pose challenges during vaccine production. The problems include many environmental waste disposal and contamination issues and are time-consuming, costly, and inefficient. Therefore, manufacturers are emphasizing developing novel technologies to avoid using organic solvents. For example, Aphios' Vaccine Adjuvant Technology encompasses nanotechnology, and its production includes supercritical, critical, or near-critical fluids with or without polar cosolvents such as ethanol [referred to as superfluids (SFS)]. Biodegradable biopolymers are dissolved in SFS and mixed with subunit vaccines in an aqueous solution or as a slurry of nanoparticles. Therefore, such new vaccine adjuvant technologies are being developed for making biodegradable polymer nanospheres (PNS) through novel processes, which allows vaccine manufacturers to rule out the use of organic solvents. Thus, technological advancements will likely bring new trends in the vaccine adjuvants market in the coming years.

Middle East & Africa Vaccine Adjuvants Market Overview

The Middle East & Africa vaccine adjuvant market has been segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa . An increase in product approvals is a major driver for the positive growth of the vaccine adjuvants market in Saudi Arabia. The product approvals by the SAFDA will enhance the adoption of adjuvanted vaccines and accelerate their adoption in the coming years in Saudi Arabia, propelling the market growth from 2020 to 2030.

Middle East & Africa Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Vaccine Adjuvants Market Segmentation

The Middle East & Africa vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the Middle East & Africa vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Middle East & Africa vaccine adjuvants market share in 2022.

By type, the Middle East & Africa vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Middle East & Africa vaccine adjuvants market in 2022.

By country, the Middle East & Africa vaccine adjuvants market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; GSK Plc; Novavax Inc; and Phibro Animal Health Corp are some of the leading companies operating in the Middle East & Africa vaccine adjuvants market.

Product Code: BMIRE00031084

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Middle East & Africa Vaccine Adjuvants Market - Key Market Dynamics

4.1 Middle East & Africa Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
- 4.2.2 Approvals of Veterinary Vaccine Adjuvants
4.3 Market Restraints
- 4.3.1 Product Recalls and Adverse Effects
4.4 Market Opportunities
- 4.4.1 Advancements in Biotechnology and Immunology
4.5 Future Trends
- 4.5.1 Technological Advancements
4.6 Impact of Drivers and Restraints:

5. Vaccine Adjuvants Market -Middle East & Africa Market Analysis

5.1 Middle East & Africa Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
5.2 Middle East & Africa Vaccine Adjuvants Market Forecast and Analysis

6. Middle East & Africa Vaccine Adjuvants Market Analysis -by Adjuvant Class

6.1 Overview
6.2 Mineral Salt Adjuvant
- 6.2.1 Overview
- 6.2.2 Mineral Salt Adjuvant: Middle East & Africa Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Emulsion Adjuvant
- 6.3.1 Overview
- 6.3.2 Emulsion Adjuvant: Middle East & Africa Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Liposome Adjuvant
- 6.4.1 Overview
- 6.4.2 Liposome Adjuvant: Middle East & Africa Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
- 6.5.1 Overview
- 6.5.2 Others: Middle East & Africa Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Middle East & Africa Vaccine Adjuvants Market Analysis - by Type

7.1 Human Vaccine Adjuvant
- 7.1.1 Overview
- 7.1.2 Human Vaccine Adjuvant: Middle East & Africa Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Veterinary Vaccine Adjuvant
- 7.2.1 Overview
- 7.2.2 Veterinary Vaccine Adjuvant: Middle East & Africa Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Vaccine Adjuvants Market -Country Analysis

8.1 Middle East & Africa
- 8.1.1 Middle East & Africa: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
  - 8.1.1.1 Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.1.1 Overview
    - 8.1.1.1.2 Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.1.3 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.1.4 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Type
  - 8.1.1.2 South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.2.1 Overview
    - 8.1.1.2.2 South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.2.3 South Africa: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.2.4 South Africa: Vaccine Adjuvants Market Breakdown, by Type
  - 8.1.1.3 United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.3.1 Overview
    - 8.1.1.3.2 United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.3.3 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.3.4 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Type
  - 8.1.1.4 Rest of Middle East and Africa Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.4.1 Overview
    - 8.1.1.4.2 Rest of Middle East and Africa Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.4.3 Rest of Middle East and Africa Vaccine Adjuvants Market Breakdown, by Adjuvant Class
    - 8.1.1.4.4 Rest of Middle East and Africa Vaccine Adjuvants Market Breakdown, by Type

9. Industry Landscape

9.1 Overview
9.2 Growth Strategies in the Global Vaccine Adjuvants Market
9.3 Organic Developments
- 9.3.1 Overview
9.4 Inorganic Developments
- 9.4.1 Overview

10. Company Profiles

10.1 GSK Plc
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 CSL Ltd
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 Croda International Plc
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Novavax Inc
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 Phibro Animal Health Corp
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments

11. Appendix

11.1 About The Insight Partners